Journal article

Australian clinicians and chemoprevention for women at high familial risk for breast cancer

LA Keogh, JL Hopper, D Rosenthal, KA Phillips

Hereditary Cancer in Clinical Practice | Published : 2009

Abstract

Objectives: Effective chemoprevention strategies exist for women at high risk for breast cancer, yet uptake is low. Physician recommendation is an important determinant of uptake, but little is known about clinicians' attitudes to chemoprevention.Methods: Focus groups were conducted with clinicians at five Family Cancer Centers in three Australian states. Discussions were recorded, transcribed and analyzed thematically.Results: Twenty three clinicians, including genetic counselors, clinical geneticists, medical oncologists, breast surgeons and gynaecologic oncologists, participated in six focus groups in 2007. The identified barriers to the discussion of the use of tamoxifen and raloxifene f..

View full abstract

Grants

Funding Acknowledgements

This study was funded by a generous bequest from Mrs Alice Harris. Louise Keogh is an NHMRC Australian Research Training Fellow. John Hopper is an Australia Fellow of the NHMRC and Victorian Breast Cancer Research Consortium Group Leader. Kelly-Anne Phillips is the Cancer Council Victoria, John Colebatch Clinical Research Fellow. We thank the contact person at each site, the clinician participants, and Sue Kirsa and Michael Jefford for their helpful input into earlier